A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of SIM0811 Injection in Healthy Chinese Adult Subjects
Latest Information Update: 20 Feb 2026
At a glance
- Drugs SIM 0811 (Primary)
- Indications Ischaemic stroke; Myocardial infarction
- Focus Adverse reactions
- Sponsors Jiangsu Simcere Pharmaceutical
Most Recent Events
- 13 Feb 2026 According to the Simcere Zaiming media release, company has recently initiated a Phase I clinical trial at Qilu Hospital of Shandong University and has successfully completed the enrollment of the first participant.
- 13 Feb 2026 Status changed from not yet recruiting to recruiting.
- 29 Jan 2026 New trial record